Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Diabetologia

• Publication date

  2006-05-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00125-006-0269-5PMID 16685502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.

  2006cited by this paper
• CCAAT/enhancer binding protein alpha maintains the ability of insulin-stimulated GLUT4 translocation in 3T3-C2 fibroblastic cells.

  2005cited by this paper
• Adiponectin and Metabolic Syndrome

  2004cited by this paper
• The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.

  2004cited by this paper
• Role of caveolin and caveolae in insulin signaling and diabetes.

  2003cited by this paper
• Importance of Adipocytokines in Obesity-Related Diseases

  2003cited by this paper
• Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy

  2003cited by this paper
• Molecular Mechanism of Insulin Resistance and Obesity

  2003cited by this paper
• Lipolysis in the absence of hormone-sensitive lipase: evidence for a common mechanism regulating distinct lipases.

  2002cited by this paper
• Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways.

  2002cited by this paper
• Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia - The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

  2001cited by this paper
• Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver

  2001cited by this paper
• Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

  2001cited by this paper
• The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.

  2001cited by this paper
• Insulin-induced Adipocyte Differentiation

  2001cited by this paper
• Predicting CHD risk in patients with diabetes mellitus

  2001cited by this paper
• Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‐L1 adipocytes

  2001cited by this paper
• Measurement of Glucose Uptake and Intracellular Calcium Concentration in Single, Living Pancreatic β-Cells*

  2000cited by this paper
• Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity.

  1999cited by this paper
• Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

  1999cited by this paper
• Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cells

  1999cited by this paper
• Insulinotropin PACAP potentiates insulin-stimulated glucose uptake in 3T3 L1 cells.

  1999cited by this paper
• Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity.

  1999cited by this paper
• Cross-Regulation of C/EBPα and PPARγ Controls the Transcriptional Pathway of Adipogenesis and Insulin Sensitivity

  1999cited by this paper
• United Kingdom Prospective Diabetes Study(UKPDS)からのメッセージとその解釈

  1999cited by this paper
• Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.

  1998cited by this paper
• Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors

  1998cited by this paper
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

  1998cited by this paper
• Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction.

  1997cited by this paper
• Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells.

  1997cited by this paper
• Tumor Necrosis Factor-α-induced Insulin Resistance in 3T3-L1 Adipocytes Is Accompanied by a Loss of Insulin Receptor Substrate-1 and GLUT4 Expression without a Loss of Insulin Receptor-mediated Signal Transduction*

  1997cited by this paper
• Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

  1996cited by this paper
• West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.

  1996cited by this paper
• The NSY mouse: a new animal model of spontaneous NIDDM with moderate obesity

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity.

  1991cited by this paper
• Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease

  1991cited by this paper
• Mouse insulin-responsive glucose transporter gene: characterization of the gene and trans-activation by the CCAAT/enhancer binding protein.

  1990cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper

• Simvastatin therapy and risk of new-onset of diabetes mellitus in euglycemic Wistar rats

  2025cites this paper
• Signaling Pathways Behind the Effect of Atorvastatin in Glucose Homeostasis

  2025cites this paper
• Cultivo de células animales murinas y humanas: una perspectiva histórica

  2025cites this paper
• Do Statins "Shape" Diabetes Risk?

  2025cites this paper
• Comparative Effectiveness of Pitavastatin Versus Atorvastatin on Lipid Profile and Blood Sugar in Patients of Diabetic Dyslipidemia: An Open-Label Comparative Study

  2025cites this paper
• miR-33a- eta miR-27b-ren inplikazioa estatinen efektu diabetogenikoan

  2025cites this paper
• Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population

  2025cites this paper
• Metabolic Shifts Induced by Treatment with Statin Influences Circulating Concentrations of the Stress Hormone, Cortisol, but Has Different Effects on Selected Cytokines, Adipokines and Neuropeptides in Lean and Fat Lines of Young Pigs

  2025cites this paper
• Cholesterol Intake and Atorvastatin Modulate SCD1 and ELOVL6 in Rat Retroperitoneal Adipose Tissue

  2025cites this paper
• Aaptamine Inhibits Lipid Accumulation and Pparg and Slc2a4 Expression While Maintaining the Methylation of the Pparg Promoter During 3T3-L1 Adipocyte Differentiation

  2025cites this paper
• Associations of Lipid-Lowering Drugs With Blood Pressure and Fasting Glucose: A Mendelian Randomization Study

  2025cites this paper
• Anti-adipogenic and anti-obesity effects of morroniside in vitro and in vivo.

  2024cites this paper
• Machine learning‐based clustering identifies obesity subgroups with differential multi‐omics profiles and metabolic patterns

  2024cites this paper
• Statin Use and Hyperglycemia: Do Statins Cause Diabetes?

  2024cites this paper
• Association between insulin‐associated gene polymorphisms and new‐onset diabetes mellitus in statin‐treated patients

  2024cites this paper
• Risk and effect modifiers for poor glycemic control among the chinese diabetic adults on statin therapy: the kailuan study

  2024cites this paper
• Association of statins with nonalcoholic fatty liver disease in patients with diabetes

  2024cites this paper
• Advances in the molecular mechanisms of statins in regulating endothelial nitric oxide bioavailability: Interlocking biology between eNOS activity and L-arginine metabolism.

  2024cites this paper
• Mevalonate biosynthesis pathway regulates the development and survival of brown adipocytes

  2023cites this paper
• Biochemical Activation and Regulatory Functions of Trans-Regulatory KLF14 and Its Association with Genetic Polymorphisms

  2023cites this paper
• Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk

  2023cites this paper
• Hydrophilic and lipophilic statin use and risk of hearing loss in hyperlipidemia using a Common Data Model: multicenter cohort study

  2023cites this paper
• Drug-induced mitochondrial toxicity: Risks of developing glucose handling impairments

  2023cites this paper
• Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis.

  2023cites this paper
• Autophagy–urea cycle pathway is essential for the statin-mediated nitric oxide bioavailability in endothelial cells

  2023cites this paper
• Drug-induced hyperglycemia and diabetes.

  2023cites this paper
• The Benefits Outweigh the Risks of Treating Hypercholesterolemia: The Statin Dilemma

  2023cites this paper
• Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications.

  2022cites this paper
• Does Pitavastatin Therapy for Patients with Type 2 Diabetes and Dyslipidemia Affect Serum Adiponectin Levels and Insulin Sensitivity?

  2022cites this paper
• The Effects of Sesquiterpene Lactones on the Differentiation of Human or Animal Cells Cultured In-Vitro: A Critical Systematic Review

  2022cites this paper
• The Impact of Age on Statin-Related Glycemia: A Propensity Score-Matched Cohort Study in Korea

  2022cites this paper
• Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study

  2022cites this paper
• Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism

  2022cites this paper
• Statins Aggravate the Risk of Insulin Resistance in Human Muscle

  2022cites this paper
• Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes Ferroptosis-Related Senescence in Adipose Tissue

  2022cites this paper
• Undertreatment or Overtreatment With Statins: Where Are We?

  2022cites this paper
• Molecular targets of statins and their potential side effects: Not all the glitter is gold.

  2022cites this paper
• Association Between Statin Exposure and Diabetes Incidence among Privately-Insured Patients Before and After Applying a Novel Technique to Control for Selection Bias.

  2022cites this paper
• Combined Beneficial Effect of Genistein and Atorvastatin on Adipogenesis in 3T3-L1 Adipocytes

  2021cites this paper
• Predictors of the effectiveness of insulin pumps in patients with type 1 diabetes mellitus

  2021cites this paper
• The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials

  2021cites this paper
• Statins Are Associated With Increased Insulin Resistance and Secretion

  2021cites this paper
• Cardiovascular disease and risk of incident diabetes mellitus: Findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

  2021cites this paper
• Effect of Metformin and Simvastatin in Inhibiting Proadipogenic Transcription Factors

  2021cites this paper
• Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review

  2021cites this paper
• The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus

  2021cites this paper
• Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study.

  2021cites this paper
• Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol.

  2021cites this paper
• Combined Effect of Metformin and Statin

  2021cites this paper
• Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, β-Cells and Metabolome

  2021cites this paper
• Simvastatin mitigates streptozotocin-induced type 1 diabetes in mice through downregulation of ADAM10 and ADAM17.

  2021cites this paper
• Combined Effect of Metformin and Statin

  2021cites this paper
• Safety Considerations of Pharmacological Treatment

  2021cites this paper
• Statin Intolerance Clinical Guide 2018

  2020cites this paper
• Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo

  2020cites this paper
• biomedicines E ff ects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study

  2020cites this paper
• Predictive network modeling in human induced pluripotent stem cells identifies key driver genes for insulin responsiveness

  2020cites this paper
• Statin and Spirulina: Will it be an Effective combination in Management of Type 2 Diabetes and it’s Complications

  2020cites this paper
• Choosing statins: a review to guide clinical practice

  2020cites this paper
• Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study

  2020cites this paper
• Statins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms, and Clinical Implications

  2020cites this paper
• β-Cell–Specific Deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) Reductase Causes Overt Diabetes due to Reduction of β-Cell Mass and Impaired Insulin Secretion

  2020cites this paper
• Rationale for the use of metformin and exercise to counteract statin‐associated side effects

  2020cites this paper
• Exploring the role of adipsin in statin-induced glucose intolerance: a prospective open label study

  2020cites this paper
• Transcription Factor KLF14 and Metabolic Syndrome

  2020cites this paper
• Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights

  2020influential citation
• Co-Administration of Vitamin E and Atorvastatin Improves Insulin Sensitivity and Peroxisome Proliferator-Activated Receptor-γ Expression in Type 2 Diabetic Patients: A Randomized Double-Blind Clinical Trial

  2020cites this paper
• Statin Use is Associated With Insulin Resistance in Participants of the Canadian Multicentre Osteoporosis Study

  2020cites this paper
• Diabetogenic effects of cardioprotective drugs

  2020cites this paper
• Inhibition of Mevalonate Pathway Prevents Adipocyte Browning in Mice and Men by Affecting Protein Prenylation.

  2019cites this paper
• Mechanisms of statin‐induced new‐onset diabetes

  2019cites this paper
• Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice

  2019cites this paper
• Statin Toxicity: Mechanistic Insights and Clinical Implications

  2019cites this paper
• Statins and the potential for higher diabetes mellitus risk

  2019cites this paper
• Effect of high dose versus low dose of atorvastatin therapy on inflammation and coagulation factors in type 2 diabetic patients; a randomized clinical trial study

  2019cites this paper
• Assessment of effect modification of statins on new-onset diabetes based on various medical backgrounds: a retrospective cohort study

  2019cites this paper
• Definition, Diagnostic Criteria, Screening, Diagnosis, and Classification of Diabetes and Categories of Glucose Intolerance

  2019cites this paper
• Association between statin treatment and new-onset diabetes mellitus: a population based case–control study

  2019cites this paper
• Effect of Statins use on Cardiac, Diabetes, Kidney and Liver Function – An update

  2019cites this paper
• Cell Biology International

  2019cites this paper
• Association of statin therapy with incidence of type 2 diabetes among US Veterans.

  2019cites this paper
• The Pleiotropic Effects of Statins in Endocrine Disorders.

  2019cites this paper
• Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect

  2019cites this paper
• A network meta-analysis on comparative efficacy of statins focusing for prevention of contrast-induced acute kidney injury in chronic kidney disease patients undergoing percutaneus coronary intervention

  2019cites this paper
• Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up

  2019cites this paper
• Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis.

  2019cites this paper
• Statins Stimulate Hepatic Glucose Production via the miR-183/96/182 Cluster

  2019cites this paper
• Sterol structure dependence of insulin receptor and insulin-like growth factor 1 receptor activation.

  2019cites this paper
• Inflammation of adipose tissue. Is there a place for statins to correct adiposopathy?

  2019cites this paper
• Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis

  2018cites this paper
• Hypolipidaemic and Anti-inflammatory effects of Curcumin versus Atorvastatin in Type 2 Diabetic Patients

  2018cites this paper
• Integrated analysis of motif activity and gene expression changes of transcription factors

  2018cites this paper
• Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol‐dependent glucose transporter 4 translocation

  2018cites this paper
• Decline in Low-Density Lipoprotein Cholesterol by Pharmacotherapy and theRisk of New-Onset Diabetes

  2018cites this paper
• Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients

  2018cites this paper
• The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations

  2018cites this paper
• Statin therapy on glycemic control in type 2 diabetic patients: A network meta‐analysis

  2018cites this paper
• Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea

  2018cites this paper
• Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

  2018cites this paper
• Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG‐CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan

  2018cites this paper